FDA Lifts Hold On Biodel Diabetes Study; Shares Jump
This article was originally published in Scrip
Executive Summary
Shares of Biodel Inc. leaped 16.3% on Oct. 13 on news the FDA had lifted the partial clinical hold on the company's randomized, open-label, parallel group Phase IIb trial, known as Study 3-250, which was testing the company's ultra-rapid-acting concentrated insulin formulation candidate BIOD-531 in patients with insulin-treated type 2 diabetes versus Eli Lilly & Co.'s Humalog (insulin lispro) Mix 75/25.